Dose finding of Quetiapine fumarate 200mg vs 400mg in First Episode Psychosis

Study identifier:AU-SEA-0003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A naturalistic, prospective, single centre, double blinded, fixed dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200 mg per day versus 400 mg per day quetiapine fumarate in 200 drug naïve first episode psychosis patients aged 15 to 25 years.

Medical condition

Psychosis

Phase

Phase 3

Healthy volunteers

Study drug

Quetiapine Fumarate

Sex

All

Actual Enrollment

150

Study type

Interventional

Age

15 Years - 25 Years

Date

Study Start Date: 01 Jul 2003

Primary Completion Date: 01 Jan 2006

Study Completion Date: 01 Jan 2006

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Sites

Melbourne, Australia

Arms	Assigned Interventions

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

Gregor Berger

+61 3 9342 2800

gregor@unimelb.edu.au

Contact Backup

AstraZeneca Australia Study Information

+61 2 9978 3500

Investigators

Principal Investigator